Epithalon and Tumor Growth Daily exposure to the peptide in rat models of cancerous tumors reported a reduction in tumor growth, with the burden diminishing the metastasis of the cells to distant tissues
An altered intestinal barrier function can also be a result of host physiological factors (e.g., bile acids) and environmental factors (e.g., dietary components) and is not necessarily deleterious, leading to a disease phenotype
The researchers found surgically treated patients improved compared to the non-surgically treated patients regarding pain, quality of life and walking distance
Regarding regenerant concentration, for typical industrial applications, the optimal range is 2%4%
dose-dependent GI adverse events (nausea, vomiting) similar to other amylin analogues Exposure: Dose-proportional increases in Cmax and AUC Gastric Effects: Dose-dependent slowing of gastric emptying confirmed via paracetamol absorption test Appetite Suppression: Reduced ad libitum food intake at doses 1.2 mg Clinical Significance: Established feasibility of once-weekly dosing and identified dose range for Phase 2 studies
